Pulmonary langerhans cell histiocytosis secondary to Marijuana use: a case report and systematic review of the literature.
Literature review found five more case reports linking heavy cannabis use to pulmonary Langerhans cell histiocytosis.
Pulmonary langerhans cell histiocytosis secondary to Marijuana use: a case report and systematic review of the literature.
Pulmonary Langerhans Cell Histiocytosis (Pulmonary Langerhans Cell Histiocytosis) is a rare interstitial lung disease primarily affecting young to middle-aged smokers.
We present a case of a 52-year-old male with Pulmonary Langerhans Cell Histiocytosis associated with heavy cannabis use.
The patient presented with dyspnea, cough and unintentional weight loss.
The patient had a 20-year history of smoking approximately ten cannabis blunts per day.
Despite normal initial chest X-ray findings, a CT scan of his chest revealed upper lobe predominant cystic changes and emphysema.
Literature review identified five additional case reports of Pulmonary Langerhans Cell Histiocytosis associated with cannabis use, involving patients aged 16 to 59 years, with a mean age of 35.8 years.
This case underscores the potential association between heavy cannabis use and the development of Pulmonary Langerhans Cell Histiocytosis.
With the increasing prevalence of cannabis consumption, it is essential to recognize cannabis as a possible risk factor for Pulmonary Langerhans Cell Histiocytosis.
Further research is needed to understand the pathophysiological mechanisms underlying cannabis-related Pulmonary Langerhans Cell Histiocytosis.
As cannabis use becomes more prevalent with changing legislation, understanding its impact on lung health and potential role in diseases like Pulmonary Langerhans Cell Histiocytosis is increasingly important.